1135242-13-5
中文名稱
VU0357017
英文名稱
VU 0357017 hydrochloride
CAS
1135242-13-5
分子式
C18H28ClN3O3
分子量
369.9
MOL 文件
1135242-13-5.mol
更新日期
2026/05/25 11:28:39
1135242-13-5 結(jié)構(gòu)式
基本信息
中文別名
VU 0357017鹽酸鹽鹽酸 VU 0357017
英文別名
CS-2319VU0357017
CID 25010775
SID 56353039
ML071 hydrochloride
VU 0357017 hydrochloride
VU0357017 monohydrochloride
Ethyl 4-(2-(2-methylbenzamido)ethylamino)piperidine-1-carboxylate hydrochloride
VU0-357017
VU 0357017
CID-25010775
VU-0357017 HYDROCHLORIDE
VU 0357017 HYDROCHLORIDE
4-[[2-[(2-Methylbenzoyl)aMino]ethyl]aMino]-1-piperidinecarboxylic Acid Ethyl Ester Hydrochloride
所屬類別
生物化工：激動(dòng)劑抑制劑物理化學(xué)性質(zhì)
儲(chǔ)存條件Inert atmosphere,2-8°C
溶解度二甲基亞砜：≥10mg/mL
形態(tài)粉末
顏色白色至灰白色
InChI1S/C18H27N3O3.ClH/c1-3-24-18(23)21-12-8-15(9-13-21)19-10-11-20-17(22)16-7-5-4-6-14(16)2;/h4-7,15,19H,3,8-13H2,1-2H3,(H,20,22);1H
InChIKeyXKJQVUIXSBOCPP-UHFFFAOYSA-N
SMILESCl.CCOC(=O)N1CCC(CC1)NCCNC(=O)c2ccccc2C
VU 0357017鹽酸鹽價(jià)格(試劑級(jí))
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
| 2026/03/03 | S6795 | VU0357017 VU0357017 Hydrochloride | 1135242-13-5 | 5mg | 725.25元 |
| 2025/12/22 | HY-19752A | VU0357017 VU0357017 hydrochloride | 1135242-13-5 | 10mM * 1mLin DMSO | 472元 |
| 2025/12/22 | HY-19752A | VU0357017 VU0357017 hydrochloride | 1135242-13-5 | 5mg | 580元 |
常見(jiàn)問(wèn)題列表
生物活性
VU0357017 hydrochloride (CID-25010775)是一種強(qiáng)效的、中樞神經(jīng)系統(tǒng)滲透性的高選擇性 M1 激動(dòng)劑，M1是 muscarinic acetylcholine receptors (mAChRs) 的一類亞型。VU0357017 hydrochloride 可在變構(gòu)位點(diǎn)起作用以激活該受體，其EC50值為 477 nM 和 Ki值為 9.91 μM。靶點(diǎn)
| Target | Value |
|
M1 mAChR
(Cell-free assay) | 477 nM(EC50) |
|
M1 mAChR
(Cell-free assay) | 9.91 μM(Ki) |
體外研究
VU0357017 is selective for M
1
(K
i
=9.91 μM) over M
2
-M
5
mAChRs (K
i
=21.4, 55.3, 35.0, and 50.0 μM, respectively) in CHO cells.
VU0357017 (1 nM-100 μM) induces calcium release and ERK phosphorylation in a concentration-dependent manner in CHO cells.
體內(nèi)研究
VU0357017 (1-10 mg/kg, i.p.) reverses scopolamine-induced disruption of the contextual fear conditioning response.
| Animal Model: | Male Sprague?Dawley rats (380-420 g) were pretreated with scopolamine |
| Dosage: | 1, 3, 10 mg/kg |
| Administration: | A single i.p. |
| Result: | Produced a significant reversal of the scopolamine-induced deficits at a dose of 10 mg/kg. |